IMMUNIC, INC.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
IMUX$7.75+5.9%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | $25,626 | $21,533 |
| General and administrative | 7,609 | 5,292 |
| Total operating expenses | 33,235 | 26,825 |
| Loss from operations | (33,235) | (26,825) |
| Other income: | ||
| Interest income | 760 | 183 |
| Other income (expense), net | (113) | 1,169 |
| Total other income | 647 | 1,352 |
| Net loss | $(32,588) | $(25,473) |
| Net loss per share, basic and diluted | $(1.08) | $(2.51) |
| Weighted-average common shares outstanding, basic and diluted | 30,136,324 | 10,134,443 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.